

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Cabotegravir and rilpivirine for treating HIV-1

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping process, it was noted that HIV disproportionately affects people of black African origin. It was also noted that HIV is more prevalent in people of certain sexual orientation such as gay or bisexual men.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Jasdeep Hayre

Date: 01/12/2020